БЛОГ

Mar 31, 2017

How to avoid the adverse reactions of senolytics through better design

Posted by in categories: biotech/medical, life extension

Another biomarker of senescent cells could be p16, a protein whose levels increase when cells stop dividing if old and also a protein whose gene is turned off in many human cancers.

Coming back to our topic – designing senolytics that avoid the apoptosis of young, healthy cells – the ideal senolytic should accomplish two things: –turn on p53 at increased levels to determine stubborn, senescent cells to commit suicide –do that on senescent cells only.

And in order to accomplish the second part, such a drug should be ‘programmed’ to only act on those cells where it recognizes senescence-associated biomarkers. There is no single biomarker today that stains positive or negative on all types of senescence cells, but increased levels of beta-galactosidase and p16 proteins could be a welcome start to identify old cells in vivo when designing such a drug.

Read more

Comments are closed.